Literature DB >> 8851625

Distribution of azithromycin into brain tissue, cerebrospinal fluid, and aqueous humor of the eye.

S Jaruratanasirikul1, R Hortiwakul, T Tantisarasart, N Phuenpathom, S Tussanasunthornwong.   

Abstract

To measure the concentrations of azithromycin in the central nervous system, 20 patients with brain tumors (group I) received a single 500-mg oral dose of azithromycin either 24, 48, 72, or 96 h prior to the tumor removal operation and 10 patients with cataracts undergoing surgery (group II) and 7 patients scheduled to undergo lumbar puncture (group III) received the same dose of azithromycin 24 h prior to the operation or procedure. Serum from all patients, brain tissue from group I, aqueous humor from group II, and cerebrospinal fluid from group III were assayed for azithromycin concentration. The mean concentrations of azithromycin in brain tissue 24, 48, 72, and 96 h after administration were 2.63 +/- 2.58, 3.64 +/- 3.81, 0.74 +/- 0.37, and 0.41 micrograms/g, respectively. In contrast, the concentrations of azithromycin in cerebrospinal fluid and aqueous humor of the eye were very low or undetectable. Therefore, these data show that azithromycin appears to be widely distributed into brain tissue but not into cerebrospinal fluid or aqueous humor of the eye.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8851625      PMCID: PMC163212     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

1.  Activity in vitro against Toxoplasma gondii of azithromycin and clarithromycin alone and with pyrimethamine.

Authors:  F Derouin; C Chastang
Journal:  J Antimicrob Chemother       Date:  1990-04       Impact factor: 5.790

Review 2.  The pharmacokinetics of azithromycin and their clinical significance.

Authors:  H Lode
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-10       Impact factor: 3.267

3.  Concentrations of azithromycin in human tonsillar tissue.

Authors:  G Foulds; K H Chan; J T Johnson; R M Shepard; R B Johnson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-10       Impact factor: 3.267

Review 4.  Spectrum of activity of azithromycin.

Authors:  J D Williams
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-10       Impact factor: 3.267

5.  Azithromycin, a macrolide antibiotic with potent activity against Toxoplasma gondii.

Authors:  F G Araujo; D R Guptill; J S Remington
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

6.  In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection.

Authors:  R P Gladue; G M Bright; R E Isaacson; M F Newborg
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

7.  In vivo activity of the macrolide antibiotics azithromycin, roxithromycin and spiramycin against Toxoplasma gondii.

Authors:  F G Araujo; R M Shepard; J S Remington
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-06       Impact factor: 3.267

Review 8.  Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy.

Authors:  D H Peters; H A Friedel; D McTavish
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

  8 in total
  33 in total

1.  Outcome of intravenous azithromycin therapy in patients with complicated scrub typhus compared with that of doxycycline therapy using propensity-matched analysis.

Authors:  Mi-Ok Jang; Hee-Chang Jang; Uh Jin Kim; Joon Hwan Ahn; Seung-Ji Kang; Sook-In Jung; Hee-Young Shin; Kyung-Hwa Park
Journal:  Antimicrob Agents Chemother       Date:  2013-12-23       Impact factor: 5.191

Review 2.  Therapeutic Approaches for Zika Virus Infection of the Nervous System.

Authors:  Rachel P M Abrams; Jamie Solis; Avindra Nath
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

3.  High-dose glycine treatment of refractory obsessive-compulsive disorder and body dysmorphic disorder in a 5-year period.

Authors:  W Louis Cleveland; Robert L DeLaPaz; Rashid A Fawwaz; Roger S Challop
Journal:  Neural Plast       Date:  2010-02-18       Impact factor: 3.599

Review 4.  Non-surgical periodontal therapy supplemented with systemically administered azithromycin: a systematic review of RCTs.

Authors:  Sabrina L Buset; Nicola U Zitzmann; Roland Weiger; Clemens Walter
Journal:  Clin Oral Investig       Date:  2015-06-12       Impact factor: 3.573

5.  In vitro susceptibility testing of four antibiotics against Borrelia burgdorferi: a comparison of results for the three genospecies Borrelia afzelii, Borrelia garinii, and Borrelia burgdorferi sensu stricto.

Authors:  Martin Sicklinger; Ralf Wienecke; Uwe Neubert
Journal:  J Clin Microbiol       Date:  2003-04       Impact factor: 5.948

6.  Synergistic activities of azithromycin and amphotericin B against Naegleria fowleri in vitro and in a mouse model of primary amebic meningoencephalitis.

Authors:  Shannon M Soltow; George M Brenner
Journal:  Antimicrob Agents Chemother       Date:  2006-10-23       Impact factor: 5.191

7.  Azithromycin Shows Anti-Zika Virus Activity in Human Glial Cells.

Authors:  Marco Iannetta; Giuseppe Ippolito; Emanuele Nicastri
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

8.  Cerebral Mycobacterium avium abscesses: Late immune reconstitution syndrome in an HIV-1-infected patient receiving highly active antiretroviral therapy.

Authors:  Claude Fortin; Danielle Rouleau
Journal:  Can J Infect Dis Med Microbiol       Date:  2005-05       Impact factor: 2.471

Review 9.  Pharmacokinetics of antibacterial agents in the CSF of children and adolescents.

Authors:  Amanda K Sullins; Susan M Abdel-Rahman
Journal:  Paediatr Drugs       Date:  2013-04       Impact factor: 3.022

10.  Assessment of blood-brain barrier penetration of miltefosine used to treat a fatal case of granulomatous amebic encephalitis possibly caused by an unusual Balamuthia mandrillaris strain.

Authors:  Sharon L Roy; Jane T Atkins; Rosemaria Gennuso; Danny Kofos; Rama R Sriram; Thomas P C Dorlo; Teresa Hayes; Yvonne Qvarnstrom; Zuzana Kucerova; B Joseph Guglielmo; Govinda S Visvesvara
Journal:  Parasitol Res       Date:  2015-09-02       Impact factor: 2.289

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.